Clinical Library
A plain-language reference for clinicians and patients. Each entry is its own page — the mechanism, the trials one by one, an honest read of the evidence, indications, safety, reimbursement, and regulatory status. Every box on the SofPulse site links here.
A non-thermal radio signal that amplifies the body's own anti-inflammatory cascade — no drug, no heat.
The single molecule that turns a radio pulse into an anti-inflammatory response.
The field reaches roughly 5 inches into tissue, so it doesn't need skin contact to work.
Short sessions, 2–4 times a day — auto or manual mode, no clinician required.
A single device covers the full recovery arc — roughly 8 days of continuous-use capacity.
The double-blind trial that tied the clinical effect to the biology, in breast-reduction surgery.
In the blinded breast-reduction trial, treated patients reported pain roughly 57% lower at one hour.
The gap between treated and placebo patients grew over the first hours — roughly a threefold difference by hour five.
Treated patients used roughly half the opioids over the first 48 hours (p = 0.002).
A direct measurement of inflammation in the wound, not just a pain score moving.
In coronary bypass patients, tPEMF extended the evidence well beyond plastic surgery.
In CABG patients, tPEMF was associated with roughly a 70% lower morphine-equivalent dose.
The opioid-sparing effect tracked with a roughly two-day shorter median stay after bypass.
The CMS-covered indication, backed by closure-rate and new-blood-vessel data across multiple studies.
The laboratory finding that explains why wounds close faster — repair runs on new vessels.
In a high-risk paraplegic population, tPEMF was associated with a 72% reduction.
Beyond pain — the device was associated with measurably quicker closure of surgical wounds.
The most directly relevant musculoskeletal evidence — accelerated tendon repair.
Strong where SofPulse is cleared, mixed elsewhere. We stay in the lane.
The core cleared use — across plastic, cardiac, bariatric, GYN, and general surgery.
Read →Medicare-covered under NCD 270.1 since 2004 — and most eligible patients have never heard of it.
Read →Pain and inflammation relief that penetrates casts, braces, and splints.
Read →FDA-cleared, CE-marked, CMS-covered, ASAPS-endorsed — and each has its own page.
Read →Cleared for post-operative pain and edema in superficial soft tissue — the line every claim stays within.
Marked in the EU for the treatment of pain, wounds, and edema.
Medicare national coverage for PEMF in chronic wound healing, in place since 2004.
The American Society of Aesthetic Plastic Surgeons has endorsed post-operative use.
For education only.This library summarizes published research and regulatory status; it is not medical advice and does not replace a clinician's judgment. Reimbursement codes and rates reflect the 2026 CMS Physician Fee Schedule and vary by locality, payer, and documentation. SofPulse is available by prescription only.